MDWD - メディウ―ンド （MediWound Ltd.） メディウ―ンドMDWDのチャート
MDWDの企業情報
| symbol | MDWD |
|---|---|
| 会社名 | Mediwound Ltd. （メディウ―ンド） |
| 分野（sector） | Consumer Durables 耐久消費財 |
| 産業（industry） | Specialty Chemicals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing manufacturing and commercializing therapeutics products in the fields of severe burns chronic and other hard-to-heal wounds connective tissue disorders and other indications. The Company''s product NexoBrid is indicated for the removal of dead or damaged tissue known as eschar in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product EscharEx is a topical biological drug which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications. メディウ―ンドはイスラエルのバイオ医薬品会社。重度熱傷、慢性疾患、その他治癒が困難な創傷、膠原病などの分野で有効な治療法がない医療ニ―ズに対応する製品の開発、製造、商業化に従事する。同社のバイオ医薬品｢NexoBrid｣は痂皮の切除用製品として、欧州医薬品庁から承認済みである。 MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel. |
| 本社所在地 | 42 Hayarkon Street Yavne 8122745 ISR |
| 代表者氏名 | Stephen T. Wills スティーブン・T・ウィルズ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +972 8-932-4010 |
| 設立年月日 | 36526 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 76人 |
| url | www.MediWound.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mdwd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.75100 |
| 終値（lastsale） | 6.36 |
| 時価総額（marketcap） | 172857416.04 |
| 時価総額 | 時価総額（百万ドル） 165.24730 |
| 売上高 | 売上高（百万ドル） 2.82000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 138.24330 |
| 当期純利益 | 当期純利益（百万ドル） -14.47300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Mediwound Ltd revenues increased 26% to $1.6M. Net loss decreased 1% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development net decrease of 65% to $1.2M (expense) General and administrative decrease of 40% to $989K (expense). |
MDWDのテクニカル分析
MDWDのニュース
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO 2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy 2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for 2019/11/05 15:31:17 Zacks Investment Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut 2019/06/19 11:51:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Cardiovascular Systems Inc (NASDAQ: CSII ) Cortexyme Inc (NASDAQ: CRTX ) EXACT Sciences Corporation (NASDAQ: EXAS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Merck & Co., Inc. (NYSE: MRK ) ( Keytruda received one more approval, this time for metastatic small cell lung cancer in patients who have been treated previously) Novocure Ltd (NASDAQ: NVCR ) Repligen Corporation (NASDAQ: RGEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Zynex Inc. (NASDAQ: ZYXI ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 18) Abeona Therapeutics Inc (NASDAQ: ABEO ) BioNano Genomics Inc (NASDAQ: BNGO ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kezar Life Sciences Inc (NASDAQ: KZ ) Mediwound Ltd (NASDAQ: MDWD ) MEREO BIOPHARMA/ADR (NASDAQ: MREO ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many …
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates 2019/05/21 12:25:04 Zacks Investment Research
MediWound (MDWD) delivered earnings and revenue surprises of -7.14% and -23.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy 2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for 2019/11/05 15:31:17 Zacks Investment Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut 2019/06/19 11:51:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Cardiovascular Systems Inc (NASDAQ: CSII ) Cortexyme Inc (NASDAQ: CRTX ) EXACT Sciences Corporation (NASDAQ: EXAS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Merck & Co., Inc. (NYSE: MRK ) ( Keytruda received one more approval, this time for metastatic small cell lung cancer in patients who have been treated previously) Novocure Ltd (NASDAQ: NVCR ) Repligen Corporation (NASDAQ: RGEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Zynex Inc. (NASDAQ: ZYXI ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 18) Abeona Therapeutics Inc (NASDAQ: ABEO ) BioNano Genomics Inc (NASDAQ: BNGO ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kezar Life Sciences Inc (NASDAQ: KZ ) Mediwound Ltd (NASDAQ: MDWD ) MEREO BIOPHARMA/ADR (NASDAQ: MREO ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many …
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates 2019/05/21 12:25:04 Zacks Investment Research
MediWound (MDWD) delivered earnings and revenue surprises of -7.14% and -23.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy 2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for 2019/11/05 15:31:17 Zacks Investment Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut 2019/06/19 11:51:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Cardiovascular Systems Inc (NASDAQ: CSII ) Cortexyme Inc (NASDAQ: CRTX ) EXACT Sciences Corporation (NASDAQ: EXAS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Merck & Co., Inc. (NYSE: MRK ) ( Keytruda received one more approval, this time for metastatic small cell lung cancer in patients who have been treated previously) Novocure Ltd (NASDAQ: NVCR ) Repligen Corporation (NASDAQ: RGEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Zynex Inc. (NASDAQ: ZYXI ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 18) Abeona Therapeutics Inc (NASDAQ: ABEO ) BioNano Genomics Inc (NASDAQ: BNGO ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kezar Life Sciences Inc (NASDAQ: KZ ) Mediwound Ltd (NASDAQ: MDWD ) MEREO BIOPHARMA/ADR (NASDAQ: MREO ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many …